Wootzano Case Exposes Fault Lines in Innovate UK Loans

What happened to Wootzano

Wootzano, a robotics firm that developed sensor-equipped robots with a "sensing skin" for fruit and vegetable packing, faced a liquidation hearing at the Court of Session in Edinburgh on 30 April 2025, as first reported by BusinessCloud. The petition to wind up the company was brought by Innovate UK Loans Limited, part of UK Research and Innovation (UKRI), over an unpaid innovation loan of £838,000 drawn in 2022.

The company had received over £2.5 million in combined Innovate UK grants and loans, according to an Innovate UK spokesperson. It had expanded into the United States. Joint liquidators' reports submitted to the court identified approximately £237 million in contracted distribution agreements, according to a source cited by BusinessCloud. Founder Dr Atif Syed separately claimed the company had signed contracts worth £537 million.

Despite those figures, the company's bank accounts have been frozen for months as a consequence of the court proceedings, according to the same source. That freeze left Wootzano unable to fund legal representation to challenge the action, creating what Dr Syed described last year as a "procedural trap."

Dr Syed claimed that Innovate UK Loans placed the loan into default after a funded subsystem failed to reach commercialisation. He stated the loan agreement allowed for discretion, restructuring or deferment at that stage. Options such as loan-to-equity conversion were discussed but never progressed, he said. He also claimed that enforcement continued with Innovate UK Loans allegedly relying on 2022 accounts rather than current data, and that senior leadership within Innovate UK and UKRI were not aware a petition existed.

"A functioning DeepTech company can be silenced without ever being heard. This is not how innovation should die."

Innovate UK declined to comment on the individual case but said in a statement last year that its loans are "patient capital and are flexible" and that "innovation is inherently risky and new technologies, markets and businesses can fail."

How the Innovation Loans programme works, and where it may fall short

The Innovation Loans programme was designed to bridge a specific gap: the space between late-stage research and development and commercial viability, where traditional lenders rarely operate. Innovate UK describes the product as patient, flexible capital for high-growth innovators. The loans sit within UKRI's broader mandate to support technologies that are too risky for conventional finance.

In principle, that mandate implies a tolerance for the non-linear trajectories common in deep-tech commercialisation. Hardware companies in particular face long development cycles, regulatory hurdles, and capital-intensive scaling phases that do not map neatly onto standard repayment schedules.

The question raised by the Wootzano case is whether enforcement practice matches that stated philosophy. Dr Syed claimed that when a funded subsystem did not commercialise on schedule, "no flexibility was offered" and the case moved directly into a standard debt-enforcement route, according to BusinessCloud. He labelled the scheme an "insolvency accelerator" on social media last year.

Portfolio-level data shared by Dr Syed paints a broader picture. The figures, which he attributed to Innovate UK's own records, showed 290 companies funded through the programme. Of those, 228 remained active, 44 were in liquidation or administration, and 17 had been dissolved. That amounts to 61 companies, or 21% of the portfolio, that were already gone.

Business Fortitude has not independently verified these figures. However, for context, the British Business Bank's Start Up Loans programme reported a cumulative default rate of around 9% in its 2023 annual report, albeit across a different risk profile and loan size. Early-stage venture debt portfolios typically see loss rates of 5% to 15%, according to industry benchmarks cited by the British Private Equity & Venture Capital Association. A 21% combined liquidation, administration and dissolution rate, if accurate, would sit at the upper end of that range or above it.

That does not necessarily indicate programme failure. Innovation loans are explicitly designed for higher-risk ventures. But it does raise a question about whether the enforcement mechanism, once triggered, operates with the patience the programme's marketing implies.

The gap between marketing and mechanism

The structural issue is straightforward. If a loan is marketed as patient capital with contractual flexibility, but enforcement follows a conventional creditor's playbook, the instrument's risk profile is materially different from what founders may expect when they sign. For a deep-tech SME with lumpy revenue, long sales cycles, and asset-light balance sheets, a winding-up petition can be terminal, not because the business has failed commercially, but because the legal process itself destroys the conditions needed for recovery.

Dr Syed said he had been contacted by other founders, investors, academics, and people inside Innovate UK and UKRI who shared similar experiences of the programme, according to BusinessCloud.

The Scottish legal wrinkle founders should know about

A lesser-known procedural point sits at the centre of Wootzano's predicament. Under Scottish court rules, a company cannot appear before the Court of Session without instructing a solicitor. A director cannot address the court directly on the company's behalf.

This differs from the position in England and Wales, where company directors may, in certain circumstances, represent their company in person before the courts, including in insolvency proceedings. The distinction matters because a winding-up petition that freezes a company's accounts simultaneously removes its ability to pay for legal representation in the jurisdiction where it must defend itself.

The result, as Dr Syed framed it, is circular. The petition freezes the funds; the freeze prevents the company from instructing a solicitor; without a solicitor, the company cannot be heard; without being heard, the petition proceeds largely unopposed. It took several months to return the matter to court, according to a source cited by BusinessCloud.

This is not a flaw unique to innovation loans. It is a feature of Scottish civil procedure that affects any company facing a winding-up petition with limited liquid resources. But the combination of a government-backed creditor initiating the petition, an account freeze as a consequence, and a jurisdiction that bars self-representation creates an unusually tight procedural bind for early-stage companies registered or operating in Scotland.

What operators drawing on public capital can learn

The Wootzano case, whatever its outcome, offers several practical observations for founders, finance directors, and boards considering or already holding Innovate UK innovation loans or similar public-sector debt instruments.

First, read the enforcement clauses as carefully as the flexibility clauses. The marketing language around patient capital describes the programme's intent. The loan agreement's default triggers, cure periods, and creditor remedies describe its legal reality. Those two things may not be the same.

Second, jurisdiction matters. Companies registered in Scotland face different procedural constraints in insolvency proceedings. Boards should understand what happens if a creditor petitions in Edinburgh rather than London, and what that means for their ability to respond.

Third, account freezes can be existential. For asset-light technology companies, a frozen bank account does not merely inconvenience operations. It can sever the company's ability to defend itself, pay staff, or fulfil the very contracts that demonstrate commercial viability.

Fourth, communication breakdowns with public-sector lenders carry outsized risk. Dr Syed claimed that communication with Innovate UK Loans stopped before enforcement escalated, and that senior UKRI leadership were unaware a petition had been filed. Whether or not that account is complete, it underscores the importance of maintaining documented, multi-level engagement with any public-sector creditor.

Innovate UK's stated position, that publicly funded loans support innovation too risky for traditional finance and that not all will succeed, is reasonable on its own terms. The harder question is whether the enforcement architecture attached to those loans is calibrated for the companies they are designed to serve, or whether it defaults to a standard creditor model that is structurally incompatible with deep-tech timelines.

That question deserves a policy answer, not just a legal one.